Publicaties

1 - 3 of 3 resultaten

Sorteren op
Zoek term:

Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Instituut voor Tropische Geneeskunde

Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Christoph Hatz, Kristine Mørch, Manuel Jesús Soriano Pérez, Véronique Sydow, Peter Sothmann, et al.

BACKGROUND: Giardiasis failing nitroimidazole first-line treatment is an emerging problem in returning European travelers. We present data on the efficacy and tolerability of 2 second-line treatment regimens.

METHODS: This prospective, open-label, multicenter study assessed the efficacy and tolerability of quinacrine monotherapy (100 mg 3 times per day for 5 days) and albendazole plus chloroquine combination therapy (400 mg twice ...

Pharmacology of novel drugs against visceral leishmaniasis and African trypanosomiasis Universiteit Antwerpen

Magali Van den Kerkhof
Visceral leishmaniasis (VL) and human African trypanosomiasis (HAT) are tropical neglected diseases caused by the respective parasites, Leishmania infantum or L. dononani and Trypanosoma brucei gambiense or T. b. rhodesiense. These parasite species can cause serious infections resulting in serious clinical symptoms and eventual death when left untreated. Current treatment options for VL and HAT are less than adequate as they lack efficacy, are ...

In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series Universiteit Antwerpen

Magali Van den Kerkhof, Dorien Mabille, E. Chatelain, C.E. Mowbray, S. Braillard, Sarah Hendrickx, Louis Maes, Guy Caljon
Objectives: Three new chemical series (bicyclic nitroimidazoles, aminopyrazoles and oxaboroles) were selected by Drugs for Neglected Diseases initiative as potential new drug leads for leishmaniasis. Pharmacodynamics studies included both in vitro and in vivo efficacy, cross-resistance profiling against the current antileishmanial reference drugs and evaluation of their cidal activity potential. Methods: Efficacy against the reference laboratory ...